Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Sarepta Therapeutics Inc. (SRPT:NASDAQ) announced clinical trial results for two drugs on March 26, 2026.

"We are pleased that these early clinical results showed high levels of siRNA delivery to muscle, with no saturation of muscle siRNA uptake or dose-limiting safety signals to date. We believe this supports the differentiated potential of this siRNA platform and strengthens our belief that this approach could meaningfully change the treatment landscape for patients with FSHD and DM1," stated Louise Rodino-Klapac, Ph.D., President, Research & Development and Technical Operations at Sarepto.

"These preliminary clinical data show consistent dose-dependent increases in plasma and muscle drug exposures across clinical and nonclinical studies and suggest that the αvβ6 integrin-targeting ligand mediates robust siRNA muscle delivery, which we hypothesize will ultimately enable higher dosing and translate into clinical efficacy for patients with FSHD1 and DM1."

Myotonic dystrophy type 1 (DM1) — a multisystem, progressive disorder — is caused by the repeated replication of the DMPK gene and is the most common adult-onset type of muscular dystrophy. It affects both skeletal and smooth muscle, as well as critical internal systems like the respiratory, nervous, endocrine, and gastrointestinal systems. The disease also attacks the eyes and heart.

Facioscapulohumeral muscular dystrophy (FSHD), on the other hand, is a disease so rare that it only affects about 16,000 Americans. A genetic disease, FSHD, is caused by activation of the DUX4 gene on the 4^th chromosome, which creates toxic DUX4 proteins. The disease causes skeletal muscles to progressively weaken, usually affecting the face, shoulders, upper limbs, abdomen, pelvis, and legs.

Neither disease is currently curable, and there are little-to-no effective treatment options. Sarepta's investigational treatments, SRP-1001 and SRP-1003, are in Phase 1/2 testing for efficacy.

"A single dose of SRP-1001 resulted in a 90% to 93% reduction in the expression of genes that are abnormally activated in FSHD . . . SRP-1001 likewise rapidly reduced serum creatine kinase levels, a key marker of muscle damage," reported Tristan Manalac for BioSpace on March 26, 2026.

In July 2025, Sarepto announced it was moving away from gene therapies after its Duchenne muscular dystrophy drug, Elevidys, resulted in the deaths of two teenage patients. The deaths tanked the company's stock, which was well above US$100 per share. Since the trial announcements for SRP-1001 and SRP-1003, however, the company's shares have rebounded 30% and reached US$23.77.  

Sarepta Therapeutics Inc. is a worldwide biotech company that focuses on genetic medicine for rare diseases and is headquartered in Massachusetts, USA. The company currently has four FDA-approved drugs for treating Duchenne Muscular Dystrophy and has several other drugs in its pipeline.

Pharma Market Slowing but Still Up

Pharma and biotech funding have been in a slump compared to their previous exponential growth. In a March 26, 2026, article for Fierce Biotech, Nick Paul Taylor wrote that current spending is less than in 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

However, J. Edward Moreno of Sherwood News reported on January 14, 2026, that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."

"As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development," Moreno went on to add.

Other news outlets are echoing this sentiment. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."

Analysts Disagree on Sarepta Rating

Analysts have varying opinions on Sarepta's stock. Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D., of H.C. Wainwright & Co. issued a "Sell" rating for the company on March 26, 2026.

They wrote, "Even if SRP-1001 and SRP-1003 ultimately prove out, they are far too early-stage to offset near-term value destruction from flagging ELEVIDYS sales. This may explain why the stock’s ~35% move (vs. XBI up ~3.5%) today suggests investors had assigned little, if any, value to the siRNA programs and were wholly focused on ELEVIDYS and the PMOs previously. We reiterate our Sell rating and 12-month price target of US$5." The analysts went to say that they are waiting for proof that SRP-1001 and SRP-1003 will be clinically superior to decide if their rating should change.

Yun Zhong, Ph.D., an analyst for Wedbush, however, offered a different take, giving the company an "Outperform" rating on March 26, 2026.

Zhong went so far as to raise the 12-month price target from US$29 to US$35 based on the preliminary data coming out regarding SRP-1001 and SRP-1003. "We project SRP-1001 and SRP-1003 to enter the U.S. market in 2031 and 2032, through an accelerated approval pathway that other more advanced programs for the same indications have helped to establish," wrote Zhong on March 25, 2026.

"Despite the early stage of the programs, we see the initial data as a critical step forward for SRPT's siRNA portfolio to create significant value for the stock."

Catalysts

According to Sarepto's investor presentation, the next 18 months will hopefully show MAD (Multiple Ascending Dose) studies are expected in the second half of 2026 for both SRP-1003, while SRP-1003 should get Casi22 data at the same time. 

Another drug, SRP-1005, intended to treat Huntington's disease, is projected to commence dosing in the first half of this year, with hopes of gathering proof-of-biology data in the first half of 2027.

Ownership & Share Structure¹

Sarepta Therapeutics Inc. has a market cap of US$2.5 billion, with 104.99 million shares outstanding.

Institutions hold 89.84% of its shares, while management and insiders own 5.16%.

The remaining 5% of shares are in retail.